Fundraising FoxSARAS CAPITAL — 2025 Investments
4 investments dated 2025 · listed companies and verified rows first · show all
Kyron.bio is a biotechnology company focused on developing therapeutic drugs, with an in-house R&D and laboratory operation.
BiotechDeep TechHealthtechParis, FR
Emilia McLaughlin(Cofounder)in
Co-investorsEntrepreneur FirstHCVCVerve VenturesGSV Ventures
.jpeg){kind=logo}
Cellbyte automates regulatory workflows and data analysis for pharmaceutical drug launches, helping manufacturers prepare treatments for global markets faster.
AI & Machine LearningEnterprise SoftwareHealthtechMedical DevicesSaaSMunich, DE
Felix Steinbrenner(CEO)inDanielSamuelPhilip BrinkmannFabian Warmdt
Co-investorsFoundersX VenturesFrontline VenturesPace VenturesSoma CapitalY CombinatorFAST — by GETTYLAB+4 more
Delfa provides an AI-driven platform for clinical trial patient recruitment, centralizing calls, notes, and updates while automating repetitive tasks for clinical research site teams.
AI & Machine LearningBiotechDigital HealthHealthtechLondon, GB
Tom Farrand(CEO)inGustav Bredell(CTO)in
Co-investorsAir Street CapitalEntrepreneur FirstTranspose Platform Management
Valink Therapeutics develops bispecific antibody-drug conjugates (ADCs) for therapeutic applications, combining high-throughput discovery, antibody engineering, and medicinal chemistry capabilities.
AI & Machine LearningBiotechHealthtechMedical DevicesBoston, US
Arne Scheu(Founder)inIrsyad Khairil(Founder)in
Co-investorsHoxton VenturesLongeVCMetaplanetOxonian VenturesP53 InvestRV Invest GmbH+9 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.